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Resumen
En este documento se muestra una base de consenso en
torno a la definición, características y propiedades benefi-
ciosas de los probióticos. El contenido fue generado a partir
de la reunión científica Workshop Probióticos y Salud. Evi-
dencia Científica, que agrupó a una variedad de expertos
españoles gastroenterólogos, microbiólogos, nutricionistas,
inmunólogos y tecnólogos de alimentos, entre otros, que se
han adherido en su mayoría a las sentencias que constituyen
este documento. Para cada sentencia se establecen las aspec-
tos científicos más relevantes que la respaldan y que son
consecuencia del acuerdo al que se ha llegado tras el debate
surgido en la reunión y la evaluación posterior del contenido
por todos los expertos que han firmado este documento.
(Nutr Hosp. 2010;25:700-704)
DOI:10.3305/nh.2010.25.5.4844
Palabras clave: Probiótico. Evidencia científica. Salud gas-
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Abstract
This report shows the level of scientific consensus on
definition, characteristics and health benefits of probio-
tics. The content of the report has derived from the scien-
tific meeting: Workshop on Probiotics and Health. Scien-
tific evidence, that congregated several Spanish experts,
including gastroenterologists, microbiologists, nutritio-
nists, immunologists and food technologists, among
others, who have agreed with the statements shown in this
document. Each statement has been sustained with the
most relevant scientific aspects that were discussed
during the Workshop and the following evaluation of the
report by all experts who approved and signed it.
(Nutr Hosp. 2010;25:700-704)
DOI:10.3305/nh.2010.25.5.4844
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1. Probiotics are live microorganisms which when
administered in adequate amounts confer a
health benefit on the host
This definition was proposed by a Joint FAO/WHO
working group of experts,1 and has been widely
accepted in the scientific literature, being the most ref-
erenced definition since it was first published. In gen-
eral, aspects such as the viability of microorganisms,
oral administration and demonstrated beneficial effects
on health after consumption are permanent criteria in
most definitions that have been proposed for probi-
otics. Although not explicitly reflected, the definition
also implies that probiotics should survive passing
through the gastrointestinal tract and preserve their
beneficial capacity when they reach the sites where
they interact with the host, which explains their mecha-
nisms of action. The definition also implies the viabil-
ity of probiotics throughout the shelf life of the product
in which they are administered. Products should con-
tain the quantity of microorganisms needed to provide
the benefit.
2.  Those substances that are constituents of
microorganisms or are produced by them
should not be considered probiotics even if
they would produce a beneficial effect on
health
Some mechanisms of action relative to beneficial
effects of probiotics include, among others, the
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release of microbial enzymes in the intestine (e.g. β-
galactosidase, which hydrolyses the lactose present
in foods), the secretion of proteins and the extracellu-
lar proteins or other macromolecules associated to
microbial envelopes that interact with pattern-recog-
nising receptors in host cells2 or the production of
metabolites or peptides with antimicrobial activity
(e.g. bacteriocins). Although they are related to the
mechanisms of action by which probiotic microor-
ganisms exert their beneficial effect on the host,
these substances should not be considered to be pro-
biotics themselves because they are not live or viable
organisms. Likewise, part of the resident or
autochthonous intestinal microbiota can enable cer-
tain metabolic activities that human intestinal cells
cannot, such as the degradation of non-digestible
components in the diet, methanogenesis, gluconeo-
genesis, and detoxification of xenobiotics or the
biosynthesis of essential amino acids, vitamins and
isoprenoids. However, such activities do not neces-
sarily confer to these microorganisms the qualifica-
tion of probiotics. 
3. For a microorganism to qualify as
a probiotic, it must be scientifically
demonstrated that it
produces beneficial effects on
the health of the host
The ability to produce a beneficial effect on health is
an essential property that characterises a probiotic. In
the 21st century, it is clear that an effect on health can
and must be verified by scientific methods which guar-
antee the efficacy and safety of the agent which pro-
duces such effect. Therefore, health claims which are
not based on scientific evidence3 are not acceptable.
Thus, there must be scientific evidence showing that
the consumption of a certain microorganism produces
a specific health effect in order to support the probiotic
status.  
4. Beneficial effects on health
should be demonstrated through
studies carried out on the human
population with suitable scientific
methodology
The usual methods to provide the scientific evi-
dence of a certain effect were reviewed both by the
group of experts from WHO and FAO,1 as well as by
the working groups from PASSCLAIM;3 these two
publications therefore offer an extensive view on the
matter. There is unanimous consensus on the concept
that there is no definitive proof of a given health
effect if its efficacy has not been confirmed in indi-
viduals of the same species for which its use is
intended. Therefore, the probiotics which are
intended for human health must have proven efficacy
in studies with human subjects.
5. Laboratory or animal model studies are a
necessary requirement before performing
studies in the human population, and they
provide information regarding mechanisms of
action; however, alone they should not be
considered as sufficient proof of efficacy in
human health
The unavoidable need to demonstrate efficacy and
safety in studies carried out in human subjects should
not lead to the conclusion that laboratory or animal
model studies are superfluous or even useless. In the
case of probiotics, it is always necessary to start with an
adequate characterisation of the microorganism that is
intended to be selected for its use in humans. The ade-
quate characterisation of the microorganism, according
to the recommendations of the WHO/FAO group,1
must include its identification, including genus,
species and strain using phenotypic methods (biologi-
cal properties expressed in vitro) and genotypic meth-
ods (sequencing of its genes, especially of the
16SrRNA gene fragments, and a description of meth-
ods for its identification in biological media by specific
techniques including fingerprinting techniques such as
PFGE or similar techniques) and depositing the strain
in internationally recognised collections. Adequate
characterisation and safety studies in animal models
are necessary before use in the human population.
Moreover, laboratory and animal model studies are
ideal for understanding and illustrating the mechanism
of action of a given probiotic on human health.
6. Healthy effects demonstrated for a specific
microbial strain cannot be extrapolated or
attributable to other strains of the same species
A microbial strain is defined by the different proper-
ties and characteristics that differentiate it from other
microorganisms of its species, including phenotypic
properties (morphological, physiological, biochemi-
cal, ecological, etc.), structural properties (cytoplasmic
membrane, cell wall, capsule, etc.) and genetic proper-
ties (DNA, RNA). The strains that result from new
microbial isolates should be evaluated to demonstrate
whether a beneficial effect is present, regardless of
whether they correspond to a species in which a probi-
otic strain has been reported. The development of mol-
ecular biology methodologies has led to the identifica-
tion of different effector cell and molecule structures
that are strain-dependent and which are related to the
specific interactions between probiotic microorgan-
isms and host cells.4 Some strain-dependent character-
istics that have been described are, among others, the
production of bacterial adhesins and exopolysaccha-
rides, related to the probiotics which remain in the
intestine, immunomodulating activity and the produc-
tion of bacteriocins. Furthermore, the strain-specific
characteristics of probiotics makes it necessary to
develop DNA fingerprinting techniques in order to
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assess the authenticity of the microorganism claimed to
be a probiotic, as well as its viability in the products in
which it is administered.
7. A microbial strain properly qualified as
probiotic due to its demonstrated efficacy for a
specific indication (e.g. diarrhoea prevention) is
not necessarily valid for other indications (e.g.
allergy prevention)
Strains included in the probiotic category, depend-
ing on their characteristics, must have been proven
effective for a specific condition. This is the case of
Lactobacillus rhamnosus GG, the usefulness of which
has been demonstrated in several studies on paediatric
gastroenteritis and diarrhoea associated with treatment
with antibiotics.5-7 Nevertheless, there are no recom-
mendations for its use in other situations such as geni-
tourinary infection prevention8. Randomised, placebo-
controlled studies for intervention with L. rhamnosus
GG, carried out to compare the preventative capacity
of developing eczema and atopic sensitisation in at-risk
children have given rise to contradictory results for
eczema prevention in general and, in particular, nega-
tive results for the prevention of eczema with atopic
sensitisation.9-12
8. The effectiveness of some probiotics strains is
widely documented for specific gastrointestinal
health conditions (e.g. some types of diarrhoea,
constipation, irritable bowel and intestinal
inflammation)
One main area in which probiotics have been applied
is in the prevention and treatment of gastrointestinal
disorders. There is extensive scientific evidence docu-
menting the efficacy of certain probiotic strains in
acute processes of the digestive tract. Some of these
indications are already common in medical practice. In
contrast, the use of probiotics or prebiotics in chronic
gastrointestinal processes is still much more limited.
Recently, the World Gastroenterology Organisation
(WGO) published a practical guide on the use of probi-
otics and prebiotics in gastroenterology.13 The WGO
guide was drafted by an international group of experts
and translated into several languages; it is available on
the organisation’s website in English, French, Spanish,
Portuguese, Russian and Mandarin Chinese. It is worth
noting that the clinical guide includes a table of specific
conditions that can be treated with certain probiotics,
thereby avoiding generalised recommendations which
are not based on scientific findings. 
9. There are probiotic strains with demonstrated
efficacy for specific indications of the immune
system (e.g. prevention of infections)
Today, it is generally accepted and has been demon-
strated by both in vitro and in vivo experiments that
probiotic strains interact with the immune system of
the host.14 For example, the formulation of multiple
species contained in the probiotic preparation VSL#3
has shown a beneficial anti-inflammatory effect in
mice by way of local stimulation of epithelial innate
immune responses (increase in the synthesis of epithe-
lial TNF-α and reestablishment of intestinal perme-
ability).15
Effects on the immune system that have been repeat-
edly observed in well-conducted intervention studies
in human beings include:
– Modulation of phagocytic activaty. Lactobacil-
lus johnsonii La1 may limit low-grade chronic
inflammation due to overgrowth of intestinal bac-
teria in the elderly, decreasing phagocytosis.16 L.
rhamnosus HN001 has demonstrated its ability to
modulate innate cell immunity, increasing the
phagocytic capacity of polymorphonuclear cells
(PMN) and monocytes, as well as an increase in
the phagocytic activity of natural killer cells (NK)
in adults and the elderly.17,18 The same has been
demonstrated for Bifidobacterium lactis HN019,
although the two studies that have documented
this were carried out in a small number of sub-
jects.19,20
– Coadjuvant effect in vaccination. In studies on
the expression of activation markers and cytokine
production in in vitro cultures of dendritic cells
(derived from monocytes) and cocultivated T-
cells with different species of lactobacillus (L.
johnsonnii, L. reuteri, L. gasseri), it has been
demonstrated that dendritic cells activated as such
secrete interleukin (IL)-12 and IL-18 and polarise
the response of lymphocytes toward a Th1-type
response by inducing the secretion of interferon
(IFN)-γ but not that of IL-4 or IL-13.20 The same
has been observed with Lactobacillus fermentum
CECT5716 as its administration together with
anti-flu vaccination improves Th1 response and
the production of antibodies.22 Likewise, an adju-
vant effect in vaccination against the seasonal flu
has also been shown in milk fermented with Lac-
tobacillus casei DN 014 001 and live cultures in
yoghurt.23
– Mitigation of common winter infections.
Although various studies carried out with probi-
otics have highlighted this positive effect on
health, it cannot be attributed to one single
species or strain because the evidence available
comes either from studies that use combinations
of bacteria species,24 or studies that use one single
strain, such as L. johnsonii La125; it would be
advisable to reproduce the evidence by subse-
quent independent studies. 
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10. Scientific evidence observed for one
population group cannot be extrapolated to
other populations of different age (children
and the elderly) or physiological state (e.g.
pregnancy and breastfeeding)
Several studies have attempted to demonstrate the
efficacy and safety of probiotic in different popula-
tion groups and physiological states. The studies
which have demonstrated the scientific evidence of
probiotics can only be attributed to the strain(s)
analysed in each population group studied; they can-
not be generalised for all populations and physiologi-
cal states.26 The anatomical and physiological differ-
ences (not only in the intestinal microbiota) between
children, adults and the elderly in the healthy popula-
tion are significant, which is why every study must
normally attempt to demonstrate the efficacy of pro-
biotic bacteria in samples representative of specific
population groups. The same can be said for special
physiological states such as pregnancy and breast-
feeding. In any case, the meta-analyses which have
included different population groups have found dif-
ferent, non-extrapolative effects. In this respect, a
meta-analysis carried out by Sazawal et al.27 found
that the use of probiotics to prevent acute diarrhoea is
more effective in children than in adults. Therefore,
not all probiotics (or the combination thereof) act
equally from one given population group to another,
or in one physiological state or another, making it
therefore necessary to demonstrate their effects in
studies that are properly designed for each situation.
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